ERBB2 and in situ carcinoma: Concerning the tumour characteristics, one patient (4.3%) had an in situ carcinoma, 34.8% (n = 8) of patients had luminal A, and 60.9% (n = 14) luminal B BC, 8.7% (n = 2) being luminal B-like HER2 positive.